# DNALite Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dnalite-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.dnalite.com
- Total disclosed funding: $7.1M
- Latest round: Series A (Mar 31, 2022)
- Investors on record: 7

## About

DNALite Therapeutics, Inc. is an innovative company focused on enhancing operational efficiency through advanced analytical tools and software tailored for diverse industries, including healthcare and corporate sectors.DNALite Therapeutics, Inc. was founded in 2016 and is headquartered in San Francisco, US. The company specializes in developing software solutions for healthcare providers and corporate enterprises. The founders, Mubhij Ahmad and Timothy Day, have prior entrepreneurial experience. In March 2022, DNALite raised USD 5.60 mn in Series A funding from SOSV, bringing the total amount raised to USD 5.60 mn and the company's valuation to USD 21.15 mn.DNALite specializes in innovative solutions designed to enhance the efficiency and effectiveness of various industries through its core product offerings. The company focuses on developing advanced analytical tools and software that cater to a diverse client base, including healthcare providers, research institutions, and corporate enterprises. Their flagship product integrates sophisticated data processing capabilities with user-friendly interfaces, allowing clients to streamline their operations and derive actionable insights from complex datasets. DNALite's solutions are utilized across multiple geographical markets, including North America, Europe, and parts of Asia, addressing specific end-use cases such as patient management in healthcare and data analysis in corporate environments.DNALite generates revenue primarily through a B2B model, offering subscription-based access to its software solutions. Clients typically engage in annual contracts that provide them with continuous access to product updates, customer support, and training resources. The company's pricing structure accommodates various business sizes, ensuring accessibility for small to large enterprises. In addition to subscriptions, DNALite establishes partnerships with key distributors in targeted markets, facilitating wider reach and enhanced service delivery. Their revenue is bolstered by the demand for their specialized analytical tools, which provide significant value to users by optimizing decision-making processes and operational efficiency.As of March 2022, DNALite Therapeutics, Inc. is focusing on launching new products designed to enhance user experience and operational efficiency. The company plans to expand its market presence in Europe and Asia by the end of 2023. The recent Series A funding of USD 5.60 mn will be utilized to support the development of these new offerings and enhance the company’s marketing strategies to penetrate new geographic areas.

## Funding rounds

- Series A, Mar 31, 2022, $5.6M — SOSV
- Seed, Mar 1, 2018, $1.5M — SOSV, Blue Bear Ventures, Berkeley Catalyst Fund, University of California, Berkeley, Baldota Group, SVE Capital
- Seed, Dec 22, 2017 — SOSV, IndieBio
- Seed, Apr 5, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- Blue Bear Ventures (https://capitalatlas.ai/funds/blue-bear-ventures) — Seed
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Seed
- University of California, Berkeley — Seed
- Baldota Group — Seed
- SVE Capital (https://capitalatlas.ai/funds/sve-capital) — Seed